Guardian Pharmacy Services, Inc.

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, MCK has a market cap of 88.9B. Regarding current trading prices, GRDN is priced at $20.94, while MCK trades at $703.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas MCK's P/E ratio is 27.68. In terms of profitability, GRDN's ROE is -0.74%, compared to MCK's ROE of -1.33%. Regarding short-term risk, GRDN is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for GRDN.Check MCK's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, COR has a market cap of 56.3B. Regarding current trading prices, GRDN is priced at $20.94, while COR trades at $285.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas COR's P/E ratio is 33.64. In terms of profitability, GRDN's ROE is -0.74%, compared to COR's ROE of +2.41%. Regarding short-term risk, GRDN is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for GRDN.Check COR's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, CAH has a market cap of 37.5B. Regarding current trading prices, GRDN is priced at $20.94, while CAH trades at $155.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas CAH's P/E ratio is 24.60. In terms of profitability, GRDN's ROE is -0.74%, compared to CAH's ROE of -0.50%. Regarding short-term risk, GRDN is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for GRDN.Check CAH's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, GRDN is priced at $20.94, while ABC trades at $179.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas ABC's P/E ratio is 21.92. In terms of profitability, GRDN's ROE is -0.74%, compared to ABC's ROE of +2.52%. Regarding short-term risk, GRDN is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for GRDN.Check ABC's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, HSIC has a market cap of 8.7B. Regarding current trading prices, GRDN is priced at $20.94, while HSIC trades at $70.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas HSIC's P/E ratio is 22.26. In terms of profitability, GRDN's ROE is -0.74%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, GRDN is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for GRDN.Check HSIC's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, PBH has a market cap of 3.8B. Regarding current trading prices, GRDN is priced at $20.94, while PBH trades at $76.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas PBH's P/E ratio is 17.92. In terms of profitability, GRDN's ROE is -0.74%, compared to PBH's ROE of +0.12%. Regarding short-term risk, GRDN is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for GRDN.Check PBH's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, GRDN is priced at $20.94, while PDCO trades at $31.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas PDCO's P/E ratio is 20.48. In terms of profitability, GRDN's ROE is -0.74%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, GRDN is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for GRDN.Check PDCO's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, OMI has a market cap of 603.7M. Regarding current trading prices, GRDN is priced at $20.94, while OMI trades at $7.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas OMI's P/E ratio is -1.66. In terms of profitability, GRDN's ROE is -0.74%, compared to OMI's ROE of -0.51%. Regarding short-term risk, GRDN is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for GRDN.Check OMI's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, ZYXI has a market cap of 78M. Regarding current trading prices, GRDN is priced at $20.94, while ZYXI trades at $2.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas ZYXI's P/E ratio is -10.75. In terms of profitability, GRDN's ROE is -0.74%, compared to ZYXI's ROE of -0.24%. Regarding short-term risk, GRDN is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for GRDN.Check ZYXI's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, WGRX has a market cap of 67.5M. Regarding current trading prices, GRDN is priced at $20.94, while WGRX trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas WGRX's P/E ratio is -1.22. In terms of profitability, GRDN's ROE is -0.74%, compared to WGRX's ROE of -7.42%. Regarding short-term risk, GRDN is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for GRDN.Check WGRX's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, GEG has a market cap of 60.6M. Regarding current trading prices, GRDN is priced at $20.94, while GEG trades at $2.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas GEG's P/E ratio is -43.40. In terms of profitability, GRDN's ROE is -0.74%, compared to GEG's ROE of -0.02%. Regarding short-term risk, GRDN is less volatile compared to GEG. This indicates potentially lower risk in terms of short-term price fluctuations for GRDN.Check GEG's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, GRDN is priced at $20.94, while HX trades at $2.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas HX's P/E ratio is -1.84. In terms of profitability, GRDN's ROE is -0.74%, compared to HX's ROE of -0.13%. Regarding short-term risk, GRDN is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for GRDN.Check HX's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, RDGT has a market cap of 7.6M. Regarding current trading prices, GRDN is priced at $20.94, while RDGT trades at $1.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas RDGT's P/E ratio is -0.39. In terms of profitability, GRDN's ROE is -0.74%, compared to RDGT's ROE of -0.20%. Regarding short-term risk, GRDN is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for GRDN.Check RDGT's competition here

GRDN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GRDN stands at 1.3B. In comparison, CVET has a market cap of 0. Regarding current trading prices, GRDN is priced at $20.94, while CVET trades at $20.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GRDN currently has a P/E ratio of -12.93, whereas CVET's P/E ratio is -69.97. In terms of profitability, GRDN's ROE is -0.74%, compared to CVET's ROE of -0.06%. Regarding short-term risk, GRDN is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for GRDN.Check CVET's competition here